Cargando…
A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke
The enhanced receptor activator of nuclear factor-κB (NFκB) ligand (RANKL) and its receptor (RANK) signal have been reported to attenuate ischemic brain injury through inhibition of Toll-like receptor (TLR) 4-mediated inflammation. However, augmentation of the RANKL/RANK signal also accelerates oste...
Autores principales: | Kurinami, Hitomi, Shimamura, Munehisa, Nakagami, Hironori, Shimizu, Hideo, Koriyama, Hiroshi, Kawano, Tomohiro, Wakayama, Kouji, Mochizuki, Hideki, Rakugi, Hiromi, Morishita, Ryuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126682/ https://www.ncbi.nlm.nih.gov/pubmed/27897273 http://dx.doi.org/10.1038/srep38062 |
Ejemplares similares
-
Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice
por: Shimamura, Munehisa, et al.
Publicado: (2018) -
Inhibition of Neointima Formation through DNA Vaccination for Apolipoprotein(a): A New Therapeutic Strategy for Lipoprotein(a)
por: Kyutoku, Mariko, et al.
Publicado: (2013) -
Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis
por: Ju, Nan, et al.
Publicado: (2019) -
Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice
por: Ju, Nan, et al.
Publicado: (2022) -
Development of an IL-17A DNA Vaccine to Treat Systemic Lupus Erythematosus in Mice
por: Koriyama, Hiroshi, et al.
Publicado: (2020)